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Abstract
The expression of the matricellular protein periostin has been as-
sociated with glioma progression. In previous work we found an as-
sociation of periostin with glioma angiogenesis. Here, we screen
gliomas for POSTN expression and identify the cells that express
periostin in human gliomas. In addition, we study the role of perios-
tin in an in vitro model for angiogenesis. The expression of periostin
was investigated by RT-PCR and by immunohistochemistry. In ad-
dition, we used double labeling and in situ RNA techniques to iden-
tify the expressing cells. To investigate the function of periostin, we
silenced POSTN in a 3D in vitro angiogenesis model. Periostin ex-
pression was elevated in pilocytic astrocytoma and glioblastoma, but
not in grade II/III astrocytomas and oligodendrogliomas. The ex-
pression of periostin colocalized with PDGFRbþ cells, but not with
OLIG2þ/SOX2þ glioma stem cells. Silencing of periostin in peri-
cytes in coculture experiments resulted in attenuation of the numbers
and the length of the vessels formation and in a decrease in endothe-
lial junction formation. We conclude that pericytes are the main
source of periostin in human gliomas and that periostin plays an es-
sential role in the growth and branching of blood vessels. Therefore,
periostin should be explored as a novel target for developing anti-
angiogenic therapy for glioma.
Key Words: Angiogenesis, Glioblastoma, Glioma, Matricellular
protein, Periostin, Vasculogenesis.
INTRODUCTION
In order to find new targets for effective anti-angiogenic
therapy for gliomas, the identification of molecules that play
key roles in neovascularization is crucial. In spite of the fact
that gliomas are among the tumors with highest degree of vas-
cularization, anti-angiogenic therapies have not yielded major
improvements in clinical outcome (1). It remains unclear why
anti-angiogenic therapies largely fail, and whether the cur-
rently used drugs address all players in the complex process of
angiogenesis. Levels of vascular endothelial growth factor
(VEGF) are associated with tumor hypoxia that increases with
tumor progression. VEGF inhibitors like bevacizumab are
only used in patients with high-grade gliomas/glioblastomas
(GBM) (2). The blood vessels in GBM show proliferation of
endothelial cells, pericytes, and other mural cells, altogether
designated as microvascular proliferation. However, notable
changes in protein expression patterns of the vessel walls of
gliomas that do not yet show microvascular proliferation have
been recorded (3, 4). Given the notion that shifts in protein ex-
pression patterns have been recorded in the vasculature of
low-grade gliomas, new targets for anti-angiogenic therapies
in glioma should be explored.
In a previous study, we identified some proteins that are
specifically upregulated in tumor angiogenesis (3). Among the
proteins identified were aV-integrin and the matricelluar pro-
teins tenascin-C and, most prominently, periostin. Matricellu-
lar proteins are expressed during development, tissue repair
and cancer and contribute to angiogenesis by making the ex-
tracellular matrix permissive for new vascular sprouts (5–11).
In various epithelial tumors increased levels periostin were
found (5, 12–15) and a prominent role of periostin at sites of
metastasis was reported (16). Periostin has been associated
with glioma invasion and vasculature (3, 17–19), and recently
its interference with anti-angiogenic therapies was highlighted
(20). Most data were obtained in mouse models and data on
the expression site of POSTN in human glioma are sketchy. In
addition, the direct effects of periostin expression on glioma
angiogenesis have not yet been investigated.
In this study, we explored the expression of periostin in
human glioma samples by immunohistochemical detection of
From the Laboratory for Tumor Immunopathology, Department of Pathology
(KH, CZ, BK, DZ, MvdW, TPPvdB, JD, JMK, DAM); and; Laboratory
for Experimental Cardiology (IC, CC), Erasmus Medical Center, Rotter-
dam, The Netherlands.
Send correspondence to: Johan M. Kros, MD, PhD, Laboratory for Tumor
Immunopathology, Department of Pathology, Erasmus Medical Center,
Room Be-230-c, Wytemaweg 80, 3015 CE Rotterdam, The Netherlands;
E-mail: j.m.kros@erasmusmc.nl
Karin Huizer and Changbin Zhu contributed equally to this work.
This study was partly sponsored by the China Scholarship Council (CSC) at
the Erasmus Medical Center, Rotterdam, The Netherlands.
The authors have no duality or conflicts of interest to declare.
863VC 2020 American Association of Neuropathologists, Inc. All rights reserved.
J Neuropathol Exp Neurol
Vol. 79, No. 8, August 2020, pp. 863–872
doi: 10.1093/jnen/nlaa067
D
ow
nloaded from
 https://academ
ic.oup.com
/jnen/article-abstract/79/8/863/5869578 by Erasm
us U
niversity R
otterdam
 user on 04 August 2020
co-expression patterns and RNA in situ hybridization and
found expression of periostin by PDGFRbþ pericytes without
overlap with SOX2þ/OLIG2þ glioma stem cells. Silencing of
the POSTN gene in cultured pericytes resulted in a reduction
of angiogenic capacity, proving the importance of periostin
for glioma angiogenesis.
MATERIALS ANDMETHODS
Tissue Samples
Tissue samples of 21 GBM, 10 pilocytic astrocytomas
(PA), 19 grade II and III astrocytoma (A II/III), and 9 oligo-
dendrogliomas grade II/III (O II/III) were obtained from the
Department of Pathology, Erasmus Medical Center, Rotter-
dam (Table 1). Pathology diagnoses were in accordance with
theWHO criteria including the molecular criteria. IDH1 muta-
tion was present in 2/21 GBMs, in 18/19A II/III, and in all O
II/III. All oligodendrogliomas had 1p/19q codeletion (Table 1).
In order to make comparisons with normal brain and other
vascular lesions, we included 11 normal brain samples, 5 cav-
ernous hemangiomas (CH), 10 arteriovenous malformations
(AVM), and 10 hemangioblastomas (HB). The age and gender
distributions of the patients are shown in Table 1. All patients
had given consent for using their biomaterials and the study
was approved by the medical ethical committee of the Eras-
mus Medical Center.
RNA Isolation and RT-PCR
Fresh-frozen samples (n¼ 67) and formalin-fixed paraf-
fin-embedded (FFPE) samples (n¼ 28) were used for RNA
isolation. For each fresh-frozen sample, 10–15 sections of 20-
mm thickness were cut by a cryostat. Sections were collected
in RNase free Eppendorf tubes, snap frozen on dry ice, and
stored at –80C until RNA isolation. To verify the presence of
tumor in all the sections used for RNA isolation, 5-mm sec-
tions before and after sampling for RNA isolation were col-
lected, H&E-stained and studied by a pathologist (J.M.K.).
Total RNA was isolated using RNA-Bee (Campro, Veenen-
daal, The Netherlands) according to the instructions supplied
by the manufacturer. For FFPE samples, RNA isolation and
quality control was performed as described previously (3, 4).
Following isolation, RNA samples were diluted in
nuclease-free water, snap frozen on dry ice and subsequently
stored at –80C. Total RNA quantity was determined by
Nanodrop and RNA integrity was checked using gel electro-
phoresis. To generate cDNA, 1mg of total RNA was reverse
transcribed using the RevertAid cDNA synthesis kit (Fermen-
tas, Waltham, MA). cDNA samples were stored at –20C until
they were measured by RT-PCR. siPOSTN sequences were
purchased from Dharmacon (Cambridge, UK) (siPOSTN 1:
catalogue #: J-020118-05-0005; siPOSTN 2: catalogue #: J-
020118-06-0005). Exon-spanning TaqMan Gene Expression
Assays of periostin (Hs00170815_m1, Applied Biosystems,
Foster City, CA) was used to measure the expression of perios-
tin. Expression of HPRT1 (Hs01003267_m1) and ACTB
(Hs99999903_m1) were used as reference genes. RT-PCR to
the endothelial marker CD31 was performed in order to cor-
rect for blood vessel density in a selection of samples (n¼ 67).
PCR was performed in a 20mL reaction volume in the Applied
Biosystems 7500 Fast Real-Time PCR System. Negative con-
trols using H2O only samples were included and showed to be
negative in all cases.
Mann-Whitney U test was used to perform statistical
analysis. All glioma subgroups were compared with each
other, and p value <0.01 was considered statistically
significant.
Immunohistochemistry
FFPE samples corresponding to the same sample used
for RNA isolation were used for immunohistochemistry. Anti-
bodies for periostin, CD31, PDGFRb, SOX2, and OLIG2
were used as previously described (2) (Table 2).
Confocal Imaging
A confocal laser-scanning microscope (LSM510; Carl
Zeiss MicroImaging, Inc., Thornwood, NY) was used. A diode
laser was used for excitation of DAPI at 405 nm, an argon la-
ser for FITC at 488 nm and a HeNe-laser for Cy5 at 633 nm.
For DAPI an emission bandpass filter of 420–480 nm, for
FITC the bandpass filter of 500–530 nm, and for Cy5 a band-
pass filter of 650 nm were used.
In Situ Hybridization
The RNAscope 1 2.0 HD Brown Chromogenic Reagent
Kit and Hs-POSTN probe (#409181) were used, according to
TABLE 1. Patient and Tumor Characteristics
Mean Age(SD) Sex(m/f) IDH1wt/mut 1p/19q CodelYes/No Total
Glioblastoma 47.4 (12.7) 15/6 19/2 0/21 21
Pilocytic astrocytoma 23.4 (18.6) 3/7 10
Astrocytoma (grade II/III) 43.2 (14.8) 7/12 1/18 0/19 19
Oligodendroglioma (grade II/III) 50.7 (7.8) 6/3 0/9 9/0 9
Normal brain 49.3 (14.8) 5/6 11
Cavernous hemangioma 19.4 (11.2) 1/4 5
Hemangioblastoma 1.3 (21.2) 6/4 10
Arterio-venous malformation 39.8 (18.3) 8/2 10
SD, standard deviation; m, male; f, female; IDH1, isodehydrogenase 1; wt, wild type; mut., mutation; codel, codeletion.
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the manufacturer’s instruction (Advanced Cell Diagnostics,
Hayward, CA). Briefly, prepared slides were baked for 1 hour
at 60C prior to use. After deparaffinization and hydration, tis-
sue and cells were air-dried and treated with a peroxidase
blocker before heating in a target retrieval solution (#320043)
for 20minutes at 95–100C. Protease (#320045) was then ap-
plied for 30minutes at 40C. POSTN probe was hybridized for
2 hours at 40C, followed by a series of signal amplification
and washing steps. Hybridization signals were detected by
chromogenic reaction using DAB chromogen followed by 1:1
(vol/vol)-diluted hematoxylin (Fisher Scientific, Pittsburg,
PA) counterstaining.
Cell Culture Experiments
In order to investigate the main source of periostin, vari-
ous cell lines were used. HUVEC (ScienCell-1800), human
brain vascular pericytes (ScienCell-1200), and human astro-
cytes (ScienCell-8000) were cultured following the manual
protocols. Periostin expression in cell lysates was measured by
Western blotting using Periostin antibody (HPA012306, 1:50,
Sigma Life Sciences, St. Louis, MO). In addition, GBM cell
line U87 was cultured for 3 days. After that, U87-conditioned
media was added to the cultures of HUVECs, pericytes and
astrocytes for 3 days. The expression of periostin in the cell ly-
sate and the media was measured in the 3 cells lines by West-
ern blot.
Silencing of POSTN
Two different siRNA sequences of periostin were used
(Dharmacon, GE Health Care, Eindhoven, The Netherlands). A
mix of nontargeting siRNA (referred to as siSham) were also
obtained from Dharmacon and used as a negative control for si-
lencing. Silencing experiments were performed using transfec-
tion buffer 1, following the manufacturer’s instructions. Human
TABLE 2. Z Scores of Periostin Expression Tumors, Malformations and Normal Brain and p Values of Differences in Expression
Between Tissues
GBM PA AII/III Oligo n.b. CH HB AVM
GBM POSTN (–dCt) Z 1.10 23.50 –2.86 –2.98 0.81 0.19 0.82
p 0.27 0.00 0.00 0.00 0.42 0.85 0.41
POSTN/CD31 (–dCt) Z 0.39 –2.22 –2.69 0.06 1.80 1.13
p 0.70 0.03 0.01 0.95 0.07 0.26
PA POSTN (–dCt) Z 1.10 –3.30 –3.03 –3.39 0.25 –1.66 1.74
p 0.27 0.00 0.00 0.00 0.81 0.10 0.08
POSTN/CD31 (–dCt) Z 0.39 –2.72 –3.59 0.55 –2.88 1.78
p 0.70 0.01 0.00 0.58 0.00 0.08
AII/III POSTN (–dCt) Z –3.50 –3.30 0.49 0.18 –2.19 –3.60 –2.12
p 0.00 0.00 0.62 0.86 0.03 0.00 0.03
POSTN/CD31 (–dCt) Z –2.22 –2.72 0.32 1.53 1.29 1.10
p 0.03 0.01 0.75 0.13 0.20 0.27
Oligo POSTN (–dCt) Z –2.86 –3.03 0.49 0.38 1.91 –3.56 –1.96
p 0.00 0.00 0.62 0.71 0.06 0.00 0.05
POSTN/CD31 (–dCt) Z
p
n.b. POSTN (–dCt) Z –2.98 –3.39 0.18 0.38 –2.34 –3.43 –1.92
p 0.00 0.00 0.86 0.71 0.02 0.00 0.05
POSTN/CD31 (–dCt) Z –2.69 –3.59 0.32 –2.15 1.76 1.41
p 0.01 0.00 0.75 0.03 0.08 0.16
CH POSTN (–dCt) Z 0.81 0.25 –2.19 1.91 –2.34 0.86 1.47
p 0.42 0.81 0.03 0.06 0.02 0.39 0.14
POSTN/CD31 (–dCt) Z 0.06 0.55 1.53 –2.15 1.47 1.04
p 0.95 0.58 0.13 0.03 0.14 0.30
HB POSTN (–dCt) Z 0.19 1.66 –3.60 –3.56 –3.43 0.86 1.10
p 0.85 0.10 0.00 0.00 0.00 0.39 0.27
POSTN/CD31 (–dCt) Z 1.80 –2.88 1.29 1.76 1.47 0.68
p 0.07 0.00 0.20 0.08 0.14 0.50
AVM POSTN (–dCt) Z 0.82 1.74 –2.12 –1.96 –1.92 1.47 1.10
p 0.41 0.08 0.03 0.05 0.05 0.14 0.27
POSTN/CD31 (–dCt) Z 1.13 1.78 1.10 1.41 1.04 0.68
p 0.26 0.08 0.27 0.16 0.30 0.50
Abbreviations: GBM¼ glioblastoma; PA¼ pilocytic astrocytoma; A II/III¼ astrocytoma WHO grades II and III; OLIGO ¼ oligodendroglioma WHO grades II and III;
n.b.¼ normal brain; CH¼ cavernous hemangioma; HB¼ hemangioblastoma; AVM¼ arteriovenous malformation; POSTN¼ periostin. P< 0.05 highlighted.
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brain vascular pericytes were transfected for 24 and 48 hours.
RNA and proteins were isolated subsequently. The silencing ef-
ficiency was evaluated by RT-PCR and by Western blotting,
following the protocols that were previously described.
3D In Vitro Angiogenesis Model
Pericytes were stained with DsRed and mixed with GFP
labeled HUVECs at 1:5 ratio as described previously (21). To
create a 3D in vitro angiogenesis model, bovine collagen type
1 was used. The parameters of angiogenesis, namely: number
of tubule formation, length of tubule formation, and number
of junctions were measured following 3 days of coculturing.
These experiments were repeated 6 times.
RESULTS
POSTN Expression Is Associated With
Angiogenesis in the Glial Tumors
The RNA expression of POSTNwas corrected for vessel
density by relating it to the expression of the endothelial
marker CD31. POSTN expression was strongly elevated in PA
and GBM as compared with that in normal brain (Fig. 1A).
POSTN expression was also high in CH, HB, and AVM. The
expression was low in A II/III and O II/III. The absolute ex-
pression and expression relative to vessel density (CD31 ex-
pression) are shown in Table 2. The results of
immunohistochemistry were in line with those of the RT-PCR
(Fig. 1B–E). In GBM, the expression of periostin was present
in the perivascular area of hypertrophic and glomeruloid ves-
sels, with dissemination in the neuropil (Fig. 1B). In the PAs
expression was confined to the hypertrophied vasculature
(Fig. 1C). The expression levels of periostin in A II/III and O
II/III were comparable to those found in control brain samples
(Fig. 1D, E). In AVM and CH, periostin was variably
expressed in arteries and veins. In the HB, only a minority of
capillaries was surrounded by perivascular periostin.
POSTN Is Expressed by Pericytes
In order to characterize the cells that express periostin,
we performed double labeling fluorescent IHC. Periostin ex-
pression colocalized with PDGFRbþ pericytes (Fig. 2A).
RNA in situ hybridization revealed that periostin protein ex-
pression localized with POSTN expression in scattered cells
present just outside the cells expressing CD31 (Fig. 2B).
GFAP-positive cells did not express POSTN (data not shown).
IHC to the stem cell markers SOX2 and OLIG2 revealed that
the expression of periostin does not colocalize with SOX2 and
OLIG2-positive cells (Fig. 2C).
Pericytes Are the Main Source of POSTN
In order to study the function of POSTN, we first identi-
fied the periostin expressing cells in vitro. Western blotting us-
ing a periostin specific antibody confirmed that pericytes are
the main source of expression. In addition, periostin expres-
FIGURE 1. Results of RT-PCR to POSTN and immunohistochemistry to periostin. (A) Box plots of RT-PCR to POSTN. Highest
expression levels of POSTN were found in GBM and PA. Significantly lower levels of expression are encountered in A II/III and O
II/III. In HB and cerebral vascular malformations (CH and AVM), POSTN expression levels are high relative to A II/III and O II/III. In
normal brain (n.b.) samples, lowest expression was recorded. (B–E) Periostin immunohistochemistry in GBM. Expression is
concentrated around areas of MVP (B). The expression is confined to the proliferated vessels in PA (C). In A II/III (D) and O II/III
(E), periostin expression is found in around scattered blood vessels (100).
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sion was found in astrocytes also, but to a lesser extent than in
pericytes. No expression was detected in endothelial cells
(Fig. 3A). To investigate periostin expression in the presence
of glial tumor cells, we added the conditioned media of U87
cells to the cultured pericytes and measured the expression of
periostin after 24 hours. Glioma-conditioned media stimulated
pericytes to express higher level of periostin (Fig. 3B). In-
creased periostin expression was also obtained following cul-
FIGURE 2. Periostin is expressed by pericytes. (A) Glioblastoma tissue immunostained for periostin and the pericyte marker
PDGFRb. There is overlapping expression of PDGFRb and periostin (400). (B) RNA in situ hybridization to POSTN in
glioblastoma (lower right panel) reveals expression in scattered cells just outside of the endothelial layer. The CD31-positive
endothelial cells (lower left panel) do not overlap with this RNA expression of POSTN (40). (C) Cells expressing the stem cell
transcription markers SOX2 and OLIG-2 do not overlap with the cells expressing periostin (IHC; 40; DAPI counterstaining).
FIGURE 3.Western blotting to POSTN in cell cultures of various lineages. (A)Western blots for periostin in cell cultures of HUVEC
(endothelial cells), pericytes, and normal astrocytes. POSTN expression is high in pericytes while expression is lower in astrocytes
and absent from HUVEC. (B) Periostin protein expression by cultured pericytes w/wo cell lysates of the glioma cell line U87, or
U87-conditioned media (U87-CM). Increased expression of periostin is observed following the addition of U87-CM, and after
culturing the pericytes in the presence of U87 cell lysates.
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FIGURE 4. In vitro angiogenesis following silencing of POSTN. (A) Bar diagram of RT-PCR results showing the successful silencing of
POSTN by 2 siRNAs. (B)Western blots showing levels of periostin in pericyte cell lysates and conditionedmedia, following silencing of
POSTN in the pericytes. Silencing by sequence #2 resulted in significant reduction of periostin expression in the pericyte cell lysates
and conditioned media. Silencing by sequence #1 resulted in reduced expression only in the conditioned media, not in the cell
lysates. (C) Images of the 3D angiogenesis culture assay (pericytes stained with DsRed, HUVEC expressing GFP) using different
conditions: Off-target silencing sequences (siSham) did not affect the formation of the blood vessels (upper panel right); effective
silencing of POSTN resulted in significant reduction of formation of angiogenesis for both sequences (lower panels). (D) Bar diagrams
showing the results of POSTN silencing in the pericytes on angiogenesis. For both silencing sequences, significant reductions in
numbers of tubules (middle panel), tubular lengths (right panel), and number of vascular junctions (left panel) was achieved.
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turing the pericytes in the presence of U87 cell lysates
(Fig. 3B).
POSTN Effect on In Vitro Angiogenesis
In functional assays, we silenced POSTN in pericytes
and used a 3D in vitro angiogenesis assay. Silencing POSTN
was achieved by 2 different siRNA sequences and POSTN
was successfully downregulated using siPOSTN for both
sequences (n¼ 3; mean 6 SEM; p¼ 0.005) (Fig. 4A). Effec-
tive downregulation of periostin protein in conditioned media
and cell lysates of the cultured pericytes was achieved by us-
ing sequence #2. Following the use of sequence #1, downregu-
lation of POSTN expression was only detected in the
conditioned media, not in the cell lysates (Fig. 4B). The peri-
cyte cultures silenced for POSTN were cocultured with endo-
thelial cells in the 3D in vitro angiogenesis model. The
number and length of the tubules and the number of junctions
formed in the assay revealed significant differences for both
silencing sequences (Fig. 4C, D).
In Vitro Angiogenesis Following Silencing of
POSTN Partially Restored in the Presence of U87
Cells or U87 Conditioned Medium
The effects of silencing of periostin on angiogenesis
was measured following the introduction of U87 (glioma)
cells and following the addition of U87-conditioned media to
the culture system. The angiogenesis-inhibiting effect of
POSTN silencing in pericytes was partially saved by the addi-
tion of U87 cells or conditioned medium (Fig. 5A, B). The
effects of silencing were stronger by using sequence #2.
FIGURE 5. In vitro angiogenesis following silencing of POSTN in the presence of U87 cells or U87-conditioned medium. (A)
Images of the angiogenesis culture assay following silencing of POSTN (using 2 different sequences) combined with U87 cells or
U87 condition medium. (B) Quantification of the numbers and lengths of tubes and junctions. The effects of silencing POSTN on
the number of vascular tubes, their length and the number of junctions were reduced in the presence of U87 cells or U87-
conditioned medium.
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DISCUSSION
In this study, we investigated the expression of periostin
in gliomas of various malignancy grades and found the highest
levels of expression in gliomas with proliferated microvascu-
lature, that is, GBM and PA. Periostin expression appeared
also to be high in other cerebral lesions with angiogenic activ-
ity, like HB and vascular malformations. In gliomas of lower
malignancy grade, in which no visible changes of the vessel
walls exist, the expression levels were comparable to those in
normal brain. Both in the tissue samples of the patients and in
the cell cultures, periostin was expressed by PDGFRbþ peri-
cytes. However, in the cell cultures low-level expression by
astrocytes was also observed. In the functional studies, we
showed that periostin expression is necessary for proper for-
mation of vasculature and that the presence of glioma cells (or
their secretome) positively influences the angiogenesis-
promoting effects of periostin.
Periostin is a matricellular protein and member of the tu-
mor growth factor (TGF) family and its expression is induced
by TGF-b and BMP-2 (22). Periostin promotes the incorpora-
tion of tenascin-C into the extracellular matrix (23) and inter-
acts with bone morphogenic proteins 1/2 (BMP1/2) for the
regulation of collagen cross-linking (24). Periostin interacts
with various matricellular proteins in reparative processes and
plays a role in the epithelial-mesenchymal transition in the
context of neoplasia (2, 23–27). In recent years, it became
clear that periostin plays roles in the proliferation, migration
and the epithelial-mesenchymal transition of cancer (28–31).
In breast cancer, periostin is expressed by tumor associated
fibroblasts and promotes the proliferation and metastatic ca-
pacities of the tumor cells (32, 33). The N-terminal region of
the molecule binds to integrins aVb3, aVb5, and a6b4
through its FAS domain (28), thereby promoting migration of
tumor cells via the activation of Akt/PKB and focal adhesion
kinase-mediated signaling pathways (14). In accordance,
knock-down of POSTN in the ErbB2/Neu-driven murine
breast tumor model results in reduced activity of the Notch
signaling pathway and deceleration of tumor growth (34, 35).
In breast and colonic cancer, it was shown that the expression
of periostin by stromal cells is induced by tumor cells and is
associated with cell proliferation, immune evasion, migration
and genomic instability and decreases apoptosis of cancer
cells (14, 36, 37). Periostin was associated with angiogenesis
in wound healing and vascular heart disease, and also in neo-
plasia (38–44). In breast cancer-associated angiogenesis, the
endothelial cells that navigate the branching of newly formed
vessels, the vascular tip cells, also transiently express periostin
(45).
To date, only few studies have focused on the expres-
sion of periostin in glial neoplasms and its expression was as-
sociated with tumor cell invasion (3, 17, 20, 46, 47). In
contrast to periostin, the matricellular proteins tenascin-C and
integrin-aV have been strongly associated with glioma angio-
genesis (48–52). It is likely that endothelial cells and pericytes
are responsible for the perivascular expression of tenascin-C
while the proliferating glial tumor cells are the extravascular
source of this protein (53, 54). The expression of tenascin-C is
induced by several angiogenic factors, including VEGF, acidic
and basic fibroblast growth factors (FGF), platelet-derived
growth factor (PDGF), and tumor necrosis factor (TNF) (55).
The perivascular presence of tenascin-C correlates with micro-
vessel density and tumor cell proliferation (49, 50, 52, 53).
Therefore, tenascin-C was selected as target for experimental
tumor therapy with the use of radio-labeled anti-tenascin-C
monoclonal antibodies (55). Integrin-aV is another molecule
that interacts with periostin and not only plays a role in angio-
genesis, but also in the proliferation, migration and invasion of
the tumor cells (56). Integrins coordinate the interaction of the
extracellular matrix with the cytoskeleton. Tenascin-C prefer-
entially binds to integrin-aVb3 (56). The expression of integ-
rin-aV is increased during physiological angiogenesis (56, 57)
and has been found upregulated in vascular malformations just
as we found to be the case with respect to periostin (58). In the
CNS, VEGF triggers the expression of integrin-aV by
pericytes and endothelial and glial cells. The expression of
integrin aVb3 parallels the progression from low-grade to
high-grade tumors (5, 59–61). Literature data point to upregu-
lation of periostin expression by hypoxia and VEGF-driven
angiogenesis (62–66). However, the expressional regulation
seems more complex from the present findings. We found
high expression of periostin in GBM as opposed to low ex-
pression in the lower-grade gliomas in which hypoxia is not
yet dominant. However, hypoxia certainly drives angiogenesis
in GBM, but the vascular proliferation in PA seems not essen-
tially hypoxia-driven while the hypertrophied vasculature dif-
fers in architecture and protein expression patterns (67). We
conclude that periostin expression contributes to aberrant an-
giogenesis, both in malformations and in gliomas, and that the
formation and structure of the malformed blood vessels is a re-
sult of the cellular and environmental context of its
expression.
Recently, it was suggested that periostin plays a role in
the maintenance of stem cells in normal bone marrow and in
the maintenance of leukemia-initiating cells (68). Among vari-
ous extracellular matrix proteins, periostin was identified as
important for the glioma stem cell niche (69). A similar effect
of periostin on breast cancer stem cells has been described
(32). In mice, it was shown that glioma stem cells defined by
expression of SOX2 and OLIG2 produce periostin that stimu-
lates the recruitment of tumor-associated macrophages
through aVb3 integrin signaling. In addition, periostin remod-
els the tumor micro-environment in concert with osteopontin
and proteins of the CNN family by interaction with tumor-
associated macrophages and other immune cells (69). Follow-
ing their arrival in the brain, monocytes differentiate into
M2-like macrophages that promote tumor progression and
counteract the antitumor effects of T lymphocytes. In GBM
the secretion of periostin was preferentially seen around cells
marked by OLIG2 and SOX2 (69). In this study, we identified
the PDGFRbþ pericytes as the source of periostin production.
The perivascular RNA expression and the overlap with the
protein by scattered cells corroborate this finding. In another
recent paper, periostin secretion has been associated with gli-
oma cell invasion, adhesion, migration and stem cell survival
in gliomas, and correlates directly with glioma grade (70).
Periostin expression was reportedly found in tumor cells but
no double labeling for GFAP or other markers was provided.
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The association between the expression levels of periostin on
the one hand, and glioma grade and patient survival on the
other, was explained by the increase in angiogenesis during
glioma progression (70). Although we found expression of
periostin in cultured astrocytes, we were unable to detect any
expression in astrocytic tumor cells in the human glioma sam-
ples. We are, however, unable to confirm expression of perios-
tin by any of the numerous cells expressing OLIG2 or SOX2,
and we did not observe its overlap with the expression of
SOX2 or OLIG2. Unfortunately, Zhou et al did not include im-
munohistochemistry to PDGFR in their study, which might
have identified the true origin of periostin in their GBM sam-
ples. Therefore, we are unable to confirm expression of perios-
tin by glioma tumor cells or glioma stem cells. The data
indicate that the periostin expression in mice is only partly re-
capitulated in man.
In conclusion, periostin expression in gliomas serves a
variety of functions that relate to neo-angiogenesis, an associa-
tion that is also present in cerebral vascular malformations.
The expression is significant in gliomas with microvascular
proliferation (GBM and PA). We identified PDGFRþ peri-
cytes as the source of periostin, a finding that is relevant to
new anti-angiogenic strategies in glioma.
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